Excellent post. It certainly appears that all the parts that IHL will need to deliver a genuine drug are being carefully put in place. Robert Clark’s appointment certainly adds significant weight to what is already a very capable scientific and corporate team.
IHL-42X (OSA) is the flagship, but there also 5 other equally exciting clinical programs.
As to value, if IHL-42x becomes a genuine registered treatment option for OSA then how do you measure that value within a significant economic market?
Frost & Sullivan estimated that undiagnosed OSA costs the US circa US$149.6 billion per year (that study was in 2015). Diagnosed OSA cost US$12.4 billion (again in 2015).
Resmed just announced full year revenue of $3.6 billion (up 12%) and declared a 44c dividend. Resmed have a market cap of $34.6 billion. In simple terms they’re trading on a MC of 10 times revenue.
I recall @andres provided a value case for IHL based on penetrating a percentage of the OSA market or a percentage of Resmed’s market share. This seems like a good way to derive a ballpark number. Perhaps he could repost his findings?
IHL Price at posting:
32.5¢ Sentiment: Buy Disclosure: Held
